Cullinan (CGEM) news
Recent news
Cullinan Therapeutics shares reverse premarket course; last down 4.2%
AInvest Wire · Aug 13, 2026Cullinan Therapeutics shares rise 12.3% premarket after lung cancer drug meets late-stage trial goal
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) shares rose 12.3% in premarket trading on August 13, 2026, following the announcement that its experimental lung cancer drug, zipalertinib, met key endpoints in late-stage clinical trials. The drug, developed in collaboration with Taiho Pharmaceutical Co.,…
AInvest Wire · Aug 13, 2026Cullinan Therapeutics Q2 EPS USD -0.81 vs. IBES estimate USD -0.81
AInvest Wire · Aug 6, 2026Cullinan Therapeutics - to initiate Phase 2 registrational study of CLN-049 in AML in Q3 2026
AInvest Wire · Jul 28, 2026Fitch affirms Cullinan at 'B-'; removes rating watch negative; outlook stable
Fitch Ratings has affirmed Cullinan’s credit rating at 'B-' with a stable outlook, marking a shift from its previous "Rating Watch Negative" status . This update reflects a reassessment of the company’s financial position and risk profile. The removal of the negative rating watch indicates that…
AInvest Wire · Jun 18, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.